77 results on '"Frölich, Lutz"'
Search Results
2. Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay
3. Inflammatory biomarkers in Alzheimer's disease plasma
4. Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort
5. Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum
6. Subjective cognitive decline and rates of incident Alzheimer's disease and non–Alzheimer's disease dementia
7. Enrichment factors for clinical trials in mild-to-moderate Alzheimer's disease
8. The frequency and influence of dementia risk factors in prodromal Alzheimer's disease
9. The European DTI Study on Dementia — A multicenter DTI and MRI study on Alzheimer's disease and Mild Cognitive Impairment
10. Consensus guidelines for lumbar puncture in patients with neurological diseases
11. BPSD Patterns in Patients With Severe Neuropsychiatric Disturbances: Insight From the RECAGE Study
12. Combined treatment with memantine and galantamine-CR compared with galantamine-CR only in antidementia drug naïve patients with mild-to-moderate Alzheimer's disease
13. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type
14. Automatic temporal lobe atrophy assessment in prodromal AD: Data from the DESCRIPA study
15. Clinical characterization of a presenilin 1 mutation (F177S) in a family with very early-onset Alzheimer's disease in the third decade of life
16. Measurements of medial temporal lobe atrophy for prediction of Alzheimer's disease in subjects with mild cognitive impairment
17. Creating a transatlantic research enterprise for preventing Alzheimer's disease
18. Investigation of the role of rare TREM2 variants in frontotemporal dementia subtypes
19. A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort
20. The association between white matter hyperintensities and executive decline in mild cognitive impairment is network dependent
21. PREVALENCE OF VASCULAR RISK FACTORS IN DIFFERENT STAGES OF PRODROMAL ALZHEIMER’S DISEASE AND ITS INFLUENCE ON COGNITIVE DECLINE
22. Postnatal ontogeny of GTP binding protein in the human frontal cortex
23. EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF ORALLY ADMINISTERED BI 409306, A NOVEL PHOSPHODIESTERASE 9 INHIBITOR, IN TWO RANDOMIZED CONTROLLED PHASE II STUDIES IN PATIENTS WITH PRODROMAL AND MILD ALZHEIMER’S DISEASE
24. MILD NEUROCOGNITIVE DISORDER IN DSM-5: BALANCING SENSITIVITY AND SPECIFICITY BY USING OPERATIONAL CRITERIA
25. GENOMICS AND EPIGENOMICS ANALYSES IN THE EMIF-AD MULTIMODAL BIOMARKER DISCOVERY STUDY
26. RELATING CSF MARKERS NEUROGRANIN, NEUROFILAMENT-LIGHT AND YKL-40 TO Aβ, APOE ε4 AND COGNITION: RESULTS FROM THE EMIF-AD MULTIMODAL BIOMARKER DISCOVERY STUDY
27. IDENTIFYING ENRICHMENT FACTORS THAT PREDICT ALZHEIMER’S DISEASE PROGRESSION: AN ANALYSIS OF THREE RANDOMIZED, CONTROLLED TRIALS
28. INCREASED CSF AMYLOID-β 1-38 AND 1-40 CONCENTRATIONS IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT WITH TAU BUT WITHOUT AMYLOID PATHOPHYSIOLOGY
29. PROBLEMS AND ISSUES OF CLINICAL SITES IN INDUSTRY SPONSORED TRIALS AND WITH CLINICAL RESEARCH ORGANIZATIONS: A EUROPEAN ALZHEIMER DISEASE CONSORTIUM (EADC) SURVEY
30. COMPARING A GERMAN VERSION OF THE FIVE WORD TEST WITH THE MINI MENTAL STATE EXAMINATION IN ITS ABILITY TO DISCRIMINATE HEALTHY CONTROLS FROM PATIENTS WITH AMNESTIC MILD COGNITIVE IMPAIRMENT AND EARLY STAGES OF ALZHEIMER’S DISEASE
31. CEREBROSPINAL FLUID AND PLASMA LEVELS OF LYSOPHOSPHATIDIC ACIDS (LPAS) ASSOCIATE WITH CEREBROSPINAL FLUID Aβ-42 AND P-TAU
32. A GENERIC LATENT VARIABLE APPROACH FOR MEASURING COGNITIVE RESERVE: PHENOTYPE VALIDATION AND GENETIC ASSOCIATION RESULTS
33. IDALOPIRDINE, A 5-HT6 ANTAGONIST, AS ADJUNCTIVE THERAPY TO ACETYLCHOLINESTERASE INHIBITORS IN PATIENTS WITH MILD-MODERATE ALZHEIMER’S DISEASE: KEY OUTCOMES FROM THE STAR PHASE III PROGRAM
34. LONGITUDINAL CEREBROSPINAL FLUID BIOMARKER TRAJECTORIES ALONG THE ALZHEIMER'S DISEASE CONTINUUM: A MULTICENTRE EUROPEAN STUDY
35. FUNCTIONAL CHARACTERIZATION OF A RARE GENETIC VARIANT IN PHOSPHOLIPASE Cγ2 WHICH IS ASSOCIATED WITH A BENEFICIAL EFFECT ON THE PROGRESSION OF ALZHEIMER’S DISEASE
36. USING EMERGING CEREBROSPINAL FLUID MARKERS TO CHARACTERIZE SUSPECTED NON-ALZHEIMER’S DISEASE PATHOPHYSIOLOGY (SNAP) IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT
37. CONCORDANCY OF AMYLOID-BETA-1-42 IN CSF AND [18F]FLORBETABEN-PET IN CLINICAL PRACTISE OF A MEMORY CLINIC
38. STUDY DESIGN AND CHARACTERISTICS OF TWO PHASE II PROOF-OF-CONCEPT CLINICAL TRIALS OF THE PDE9 INHIBITOR BI 409306 IN EARLY ALZHEIMER'S DISEASE
39. Insulin effects on CSF norepinephrine and cognition in Alzheimer's disease
40. ROLE OF PLD3 RARE VARIANTS IN EUROPEAN SPORADIC ALZHEIMER'S DISEASE PATIENTS
41. ADVANCED DIFFUSION WEIGHTING IMAGING (DWI) TRACTOGRAPHY OF THE LIMBIC SYSTEM: NOVEL BIOMARKERS OF NEURODEGENERATIVE CHANGES DURING PROGRESSION/CONVERSION FROM COGNITIVE NORMALITY TO AD DEMENTIA
42. Which MCI subtypes convert to Alzheimer's disease in spite of negative CSF findings?
43. Incidence and predictors of response to the 13.3 (15 cm2) and 9.5 mg/24h (10 cm2) rivastigmine patch in the OPtimising Transdermal Exelon In Mild-to-moderate Alzheimer's disease (OPTIMA) study
44. Performance of different research criteria and cognitive tests to predict incident Alzheimer’s disease
45. Genome-wide association study using cerebrospinal fluid biomarkers beta-amyloid-42 and pTau181 in German samples of Alzheimer's disease
46. Obesity impairs ADL and IADL in Alzheimer's disease subjects
47. 26 High-dose rivastigmine patch: results from the optima study
48. The evolution of Alzheimer's disease and its management: Data from the European ICTUS study
49. Cognitive and CSF biomarkers in older adults, MCI, and dementia
50. The prognostic value of different subtypes of mild cognitive impairment (MCI) and their association to CSF and genetic markers in the prospective cohort study descripa
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.